



1PW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Furst et al.
For : VASCULAR GRAFTS WITH
AMPHIPHILIC BLOCK
COPOLYMER COATINGS
Serial No. : 10/763,493
Filed : January 23, 2004
Our Docket : ICON 2 00043

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In accordance with the requirements of 37 CFR 1.97 and 37 CFR 1.98, Applicant cites the references which are identified on the enclosed form PTO-1449.

Consideration of the references and placement on the record is respectfully requested.

Respectfully submitted,
FAY, SHARPE, FAGAN, MINNICH & McKEE


By: 

BRIAN E. TURUNG
Reg. No. 35,394
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2579
Telephone: (216) 861-5582
Facsimile: (216) 241-1666

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on 9-14-05

Adeline Machado
(SIGNATURE)



PTO/SB/08A (6-95)
PTO/SB/08A (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(use as many sheets as necessary)

Complete if Known

Application Number 10/763,493

Filing Date	January 23, 2004
--------------------	------------------

First Named Inventor	Furst et al.
----------------------	--------------

Art Unit

Examiner Name

Attorney Docket Number	ICON 200043
------------------------	-------------

Sheet

1

9

5

Examiner Initials*	Cita No.	U.S. Patent Documents		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
		4,733,665		PALMAZ	3/29/88	
		4,776,337		PALMAZ	10/11/88	
		5,037,392		HILLSTEAD	8/6/91	
		5,116,318		HILLSTEAD	5/26/92	
		6,245,537		WILLIAMS	6/12/01	
		5,370,681		HERWECK	12/6/94	
		5,417,981		ENDO	5/23/95	
		5,609,629		FEARNOT	3/11/97	
		6,096,070		RAGHEB	8/1/00	
		6,156,373		ZHONG	12/5/00	
		5,824,049		RAGHEB	10/20/98	
		5,873,904		RAGHEB	2/23/98	
		6,322,847		ZHONG	11/27/01	
		6,358,989		KUNZ	3/19/02	
		6,356,600		KIRSTEINS	3/12/02	
		6,368,658		SCHWARZ	4/9/02	
		6,369,065		CHATELAIN	4/9/02	
		6,299,604		RAGHEB	10/9/01	
		6,530,951		BATES	3/11/03	

[illegible]

Date Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Substitute for Form 1449A/PTO) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/763,493
			Filing Date	January 23, 2004
			First Named Inventor	Furst et al.
			Art Unit	
			Examiner Name	
Sheet 2 of 5	Attorney Docket Number		ICON 200043	

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
		6,569,441		KUNZ	5/27/03	
		6,770,729		VAN ANTWERP	8/3/04	
		6,599,275		FISCHER	7/29/03	
		6,759,431		HUNTER	7/6/04	
		6,607,598		SCHWARZ	8/19/03	
		6,623,521		STEINKE	9/23/03	
		6,624,138		SUNG	9/23/03	
		6,652,575		WANG	11/25/03	
		6,656,506		WU	12/2/03	
		6,656,966		GARVEY	12/2/03	
		6,753,071		PACETTI	6/22/04	
		6,720,350		KUNZ	4/13/04	
		6,730,064		RAGHEB	5/4/04	
		6,730,349		SCHWARZ	5/4/04	
		6,734,194		END	5/11/04	
		6,743,805		END	6/1/04	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ^a	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

SEP 16 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (05-03)
Approved for use through 05/31/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(Substitute for Form 1449A/PTO)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/763,493
Filing Date	January 23, 2004
First Named Inventor	Furst et al.
Art Unit	
Examiner Name	
Attorney Docket Number	ICON 200043

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Substitute for Form 1449A/PTO) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,493
				Filing Date	January 23, 2004
				First Named Inventor	Furst et al.
				Art Unit	
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	ICON 200043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T ²
		Abstract of <i>Pharmacological Properties of Trepidil: Comparison with Other Coronary Vasodilators</i> , Ohnishi H, Kosuzume H, Yamaguchi K, Sato M, Umehara S, Funato H, Itoh C, Suzuki K, Kitamura Y, Suzuki Y, Itoh R, Nippon Yakurigaku Zasshi. 1980 Sep;76(6):495-503.	
		Abstract of <i>Effects of Trepidil on Thromboxane A2-induced Aggregation of Platelets, Ischemic Changes in Heart and Biosynthesis of Thromboxane A2</i> , Ohnishi H, Kosuzume H, Hayashi Y, Yamaguchi K, Suzuki Y, Itoh R, Prostaglandins Med. 1981 Mar;6(3):269-81.	
		Abstract of <i>Antithrombotic Activity and the Mechanism of Action of Trepidil (Rocornal)</i> , Suzuki Y, Yamaguchi K, Shimada S, Kitamura Y, Ohnishi H., Prostaglandins Leukot Med. 1982 Dec;9(6):685-95.	
		Abstract of <i>Suppression of Fibroblast Proliferation In Vitro and of Myointimal Hyperplasia In Vivo by the Triazolopyrimidine, Trepidil</i> , Tiell ML, Sussman II, Gordon PB, Saunders RN, Artery. 1983;12(1):33-50.	
		<i>Influence of Cardiovascular Drugs on Platelet Aggregation</i> , Forster W, Block HU, Giessler C, Heinroth I, Mentz P, Ponicke K, Rettkowski W, Zehl U., : Adv Myocardiol. 1983;4:539-47.	
		Abstract of <i>Trepidil in Preventing Restenosis After Balloon Angioplasty in the Ather Osclerotic Rabbit</i> , MW Liu, GS Roubin, KA Robinson, AJ Black, JA Hearn, RJ Siegel, and SB King, 3d Circulation 1990 81: 1089-1093.	
		Abstract of <i>Effects of Trepidil (Triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T, Am Heart J. 1992 Jun;123(6):1439-44.	
		Abstract of <i>Trepidil (triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty. Results of the Randomized, Double-Blind STARC Study. Studio Trepidil Versus Aspirin Nella Restenosi Coronarica</i> , A Maresta, M Balducelli, L Cantini, A Casari, R Chioin, M Fabbri, A Fontanelli, PA Monici Preti, S Repetto, and S De Serv, Circulation, Dec 1994; 90: 2710 - 2715.	
		Abstract of <i>The Trepidil Restenosis Trial (STARC study): Background, Methods and Clinical Characteristics of the Patient Population</i> , Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fontanelli A, Monici Preti PA, Repetto S, Raffaghello S., Clin Trials Metaanal. 1994 Apr;29(1):31-40.	
		Abstract of <i>Fast and Reproducible Vascular Neointima Formation in the Hamster Carotid Artery: Effects of Trepidil and Captopril</i> , Matsuno H, Stassen JM, Hoylaerts MF, Vermynen J, Deckmyn H., Thromb Haemost. 1995 Dec;74(6):1591-6.	
		<i>New Aspects in Antithrombotic Therapy--Platelet Inhibitors-</i> , Terres W, Meinertz T., Herz. 1996 Feb;21(1):1-11.	
		<i>Management of restenosis after Coronary Intervention</i> , Dangas G, Fuster V., Am Heart J. 1996 Aug;132(2 Pt 1):428-36.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, Virginia 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Substitute for Form 1449A/PTO) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,493
				Filing Date	January 23, 2004
				First Named Inventor	Furst et al.
				Art Unit	
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	ICON 200043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T ²
		<i>Results of a Meta-Analysis of Trepidil, a PDGF Inhibitor A Sufficient Reason for a Second Look to the Pharmacological Approach to Restenosis</i> , Serruys PW, Banz K, Darcis T, Mignot A, van Es GA, Schwicker D., J Invasive Cardiol. 1997 Oct;9(8):505-512.	
		<i>A Randomized Comparison of Trepidil (triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, Versus Aspirin in Prevention of Angiographic Restenosis after Coronary Artery Palmaz-Schatz Stent Implantation</i> , Galassi AR, Tamburino C, Nicosia A, Russo G, Grassi R, Monaco A, Giuffrida G., Catheter Cardiovasc Interv. 1999 Feb;46(2):162-8	
		<i>Reference Chart Derived From Post-Stent-Implantation Intravascular Ultrasound Predictor of 6-Month Expected Restenosis on Quantitative Coronary Angiography</i> , P. J. de Feyter, P. Kay, C. Disco, and P. W. Serruys, Circulation, Oct 1999; 100: 1777 - 1783.	
		<i>Trepidil Inhibits Monocyte Chemoattractant Protein-1 and macrophage Accumulation After Balloon Arterial Injury in Rabbits</i> , Poon M, Cohen J, Siddiqui Z, et al., Lab Invest. 1999;79:1369-1375.	
		<i>The TRAPIST study - A multicentre randomized placebo controlled clinical trial of trepidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound</i> , P.W. Serruys, D.P. Foley, M. Pieper, J.A. de Feyter on behalf of the TRAPIST investigators, European Heart Journal (2001) 22, 1938-1947, doi:10.1053/ehj.2001.2627, available online at http://www.idealibrary.com	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, Virginia 22313-1450